Innovative funding partner throughout the growth life-cycle

Latest developments

News, Portfolio 13/03/2023              

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of…
News, Portfolio 09/03/2023              

Ibex secures PathLAKE contracts to roll out AI-based cancer diagnostics to UK hospitals

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer…
News, Portfolio 09/03/2023              

PwC collaborates with FintechOS to launch digital banking package on Microsoft Cloud for Finance

FintechOS, a leader in fintech enablement, is to collaborate with PwC to support its new digital banking solution: Infinite Financial Solutions for Banking. Powered by Microsoft’s Cloud for Financial Services…

Subscribe to our mailing list

Get our newsletter, Kreos updates and information on our events right to your mailbox.

Market Leading Growth Debt Investor for +25 years

Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.

For over 25 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.